Abstract
To determine whether topically applied biologically active drugs can be used to protect the human immune system from sunlight, we studied the effect of tamarind xyloglucan polysaccharide, a natural and common fruit constituent, on solar-simulated, ultraviolet radiation-induced local immunosuppression and erythema in humans. Immunosuppression was studied in humans using a nickel contact hypersensitivity recall model. Ultraviolet dose responses were generated to determine the extent to which tamarind affected the immune response in a group of 15 volunteers. The subsequent nickel-induced erythema was quantitated using a reflectance spectrometer. 0.1 μgml-1 of topical tamarind polysaccharide reduced ultraviolet radiation-induced immunosuppression. Frozen sections of biopsies taken were analysed by immunohistochemistry. Tamarind inhibited ultraviolet radiation-induced CD11c+ dendritic cell loss from the epidermis. The ultraviolet doses used in this study did not alter the number of Mac387+ macrophages or NP57+ neutrophils infiltrating the skin. Low dose xyloglucan polysaccharide from tamarind protected from immunosuppression in humans, possibly by reducing ultraviolet radiation-induced loss of dendritic cells, demonstrating that these types of drugs may be useful adjuncts to sunscreens for protection from skin cancer.
Keywords: tolerance, skin, dendritic cells, tumour immunity, ultraviolet, sunlight
Letters in Drug Design & Discovery
Title: Tamarind Inhibits Solar-Simulated Ultraviolet Radiation-Induced Suppression of Recall Responses in Humans
Volume: 2 Issue: 2
Author(s): J. M. Kuchel, R. St. C. Barnetson, L. Zhuang, F. M. Strickland, R. P. Pelley and G. M. Halliday
Affiliation:
Keywords: tolerance, skin, dendritic cells, tumour immunity, ultraviolet, sunlight
Abstract: To determine whether topically applied biologically active drugs can be used to protect the human immune system from sunlight, we studied the effect of tamarind xyloglucan polysaccharide, a natural and common fruit constituent, on solar-simulated, ultraviolet radiation-induced local immunosuppression and erythema in humans. Immunosuppression was studied in humans using a nickel contact hypersensitivity recall model. Ultraviolet dose responses were generated to determine the extent to which tamarind affected the immune response in a group of 15 volunteers. The subsequent nickel-induced erythema was quantitated using a reflectance spectrometer. 0.1 μgml-1 of topical tamarind polysaccharide reduced ultraviolet radiation-induced immunosuppression. Frozen sections of biopsies taken were analysed by immunohistochemistry. Tamarind inhibited ultraviolet radiation-induced CD11c+ dendritic cell loss from the epidermis. The ultraviolet doses used in this study did not alter the number of Mac387+ macrophages or NP57+ neutrophils infiltrating the skin. Low dose xyloglucan polysaccharide from tamarind protected from immunosuppression in humans, possibly by reducing ultraviolet radiation-induced loss of dendritic cells, demonstrating that these types of drugs may be useful adjuncts to sunscreens for protection from skin cancer.
Export Options
About this article
Cite this article as:
Kuchel M. J., Barnetson St. C. R., Zhuang L., Strickland M. F., Pelley P. R. and Halliday M. G., Tamarind Inhibits Solar-Simulated Ultraviolet Radiation-Induced Suppression of Recall Responses in Humans, Letters in Drug Design & Discovery 2005; 2 (2) . https://dx.doi.org/10.2174/1570180053175106
DOI https://dx.doi.org/10.2174/1570180053175106 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Crocins: The Active Constituents of Crocus Sativus L. Stigmas, Exert Significant Cytotoxicity on Tumor Cells In Vitro
Current Cancer Therapy Reviews Recent Evidence on the Role of Dietary PUFAs in Cancer Development and Prevention
Current Medicinal Chemistry Recent Advances in the New Generation Taxane Anticancer Agents
Medicinal Chemistry Staurosporine Analogues from Microbial and Synthetic Sources and Their Biological Activities
Current Medicinal Chemistry Promiscuous Binding Nature of Sh3 Domains to their Target Proteins
Protein & Peptide Letters Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patients’ Outcome
Current Cancer Drug Targets Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeting of Lymphatics for Therapy
Current Pharmaceutical Design Apoptotic Effects of Bilirubin on Skin Cancer Cell Lines SK-MEL-3 (Melanoma) and A431 (Non-Melanoma)
Anti-Cancer Agents in Medicinal Chemistry Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Current Pharmaceutical Design Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Antisense Treatment in Human Prostate Cancer and Melanoma
Current Cancer Drug Targets Intravesical Drug Delivery into the Bladder to Treat Cancers
Current Drug Delivery Thymic Immunosuppressive Pentapeptide (TIPP) Shown Anticancer Activity in Breast Cancer and Chronic Myeloid Leukemia Both <i>In Vitro</i> and <i>In Vivo</i>
Protein & Peptide Letters Epithelial Organotypic Cultures: A Viable Model to Address Mechanisms of Carcinogenesis by Epitheliotropic Viruses
Current Topics in Medicinal Chemistry QSAR study on N- (Aryl)-4-(Azolylethyl) Thiazole-5-Carboxamides: Novel Potent Inhibitors of VEGF Receptors I and II
Medicinal Chemistry On The Edge of Validation – Cancer Protease Fibroblast Activation Protein
Mini-Reviews in Medicinal Chemistry Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin
Current Drug Discovery Technologies Regulation of Runx2 and Its Signaling Pathways by MicroRNAs in Breast Cancer Metastasis
Current Protein & Peptide Science Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation